Tg Therapeutics Inc. | Mid-cap | Healthcare
$28.77
1.62%
| Tg Therapeutics Stock Comparison:
Tg Therapeutics vs VertexTg Therapeutics vs RegeneronTg Therapeutics vs BridgeBio PharmaTg Therapeutics vs MadrigalTg Therapeutics vs Blueprint MedicinesTg Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 141.1M
Gross Profit 122.2M 86.58%
Operating Income 34.8M 24.69%
Net Income 28.2M 19.97%
EPS (Diluted) $0.17

Balance Sheet Metrics

Total Assets 702.6M
Total Liabilities 426.2M
Shareholders Equity 276.4M
Debt to Equity 1.54

Cash Flow Metrics

Operating Cash Flow 3.0M
Free Cash Flow 7.4M

Revenue & Profitability Trend

Tg Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i329.0M233.7M2.8M6.7M152.0K
Cost of Goods Sold i38.5M14.1M265.0K790.0K0
Gross Profit i290.5M219.5M2.5M5.9M152.0K
Gross Margin % i88.3%94.0%90.5%88.2%100.0%
Operating Expenses
Research & Development i94.3M76.2M125.4M222.6M165.9M
Selling, General & Administrative i154.3M122.7M70.0M128.1M107.8M
Other Operating Expenses i-----
Total Operating Expenses i248.6M198.9M195.4M350.7M273.7M
Operating Income i41.9M20.6M-192.8M-344.8M-273.6M
Operating Margin % i12.7%8.8%-6,924.2%-5,154.3%-179,996.1%
Non-Operating Items
Interest Income i-----
Interest Expense i24.0M12.6M10.2M5.6M6.3M
Other Non-Operating Income7.7M5.0M4.7M2.3M542.0K
Pre-tax Income i25.6M13.1M-198.3M-348.1M-279.4M
Income Tax i2.2M390.0K00-
Effective Tax Rate % i8.6%3.0%0.0%0.0%0.0%
Net Income i23.4M12.7M-198.3M-348.1M-279.4M
Net Margin % i7.1%5.4%-7,121.5%-5,204.1%-183,803.3%
Key Metrics
EBITDA i49.9M26.1M-187.6M-342.0M-272.7M
EPS (Basic) i$0.16$0.09$-1.46$-2.63$-2.42
EPS (Diluted) i$0.15$0.09$-1.46$-2.63$-2.42
Basic Shares Outstanding i145317418141955112135411258132222753115333693
Diluted Shares Outstanding i145317418141955112135411258132222753115333693

Income Statement Trend

Tg Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i179.9M92.9M102.3M298.9M553.4M
Short-term Investments i131.1M124.6M59.4M15.9M52.0M
Accounts Receivable i129.2M51.1M01.4M0
Inventory i110.5M39.8M0--
Other Current Assets15.7M5.3M2.4M2.9M1.1M
Total Current Assets i566.4M317.9M168.3M331.0M611.7M
Non-Current Assets
Property, Plant & Equipment i7.2M8.1M9.2M9.2M9.8M
Goodwill i-1.6M1.6M1.6M1.6M
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets3.4M1.3M1.3M1.3M1.3M
Total Non-Current Assets i11.3M11.6M25.3M48.7M13.9M
Total Assets i577.7M329.6M193.6M379.6M625.6M
Liabilities
Current Liabilities
Accounts Payable i-----
Short-term Debt i1.2M1.4M1.6M2.4M23.8M
Current Portion of Long-term Debt-----
Other Current Liabilities4.6M1.6M1.2M1.5M18.2M
Total Current Liabilities i90.7M53.7M53.2M65.4M87.6M
Non-Current Liabilities
Long-term Debt i252.6M109.3M81.5M76.6M18.1M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i264.6M115.4M81.8M77.1M18.7M
Total Liabilities i355.3M169.1M135.0M142.5M106.3M
Equity
Common Stock i156.0K151.0K146.0K143.0K141.0K
Retained Earnings i-1.5B-1.5B-1.5B-1.3B-980.6M
Treasury Stock i9.0M234.0K234.0K234.0K234.0K
Other Equity-----
Total Shareholders Equity i222.4M160.5M58.6M237.2M519.4M
Key Metrics
Total Debt i253.7M110.8M83.1M79.0M42.0M
Working Capital i475.7M264.2M115.1M265.6M524.2M

Balance Sheet Composition

Tg Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i23.4M12.7M-198.3M-348.1M-279.4M
Depreciation & Amortization i280.0K423.0K515.0K494.0K374.0K
Stock-Based Compensation i42.5M37.9M19.2M61.3M80.3M
Working Capital Changes i-132.1M-84.9M9.4M-28.2M-19.8M
Operating Cash Flow i-61.7M-29.4M-164.8M-312.1M-214.5M
Investing Activities
Capital Expenditures i-45.0K0-14.0K-401.0K-357.0K
Acquisitions i-----
Investment Purchases i-311.9M-146.9M-107.3M-55.5M-67.4M
Investment Sales i310.9M96.2M87.3M55.6M43.2M
Investing Cash Flow i-1.0M-50.7M-20.0M-332.0K-24.5M
Financing Activities
Share Repurchases i-8.8M----
Dividends Paid i---00
Debt Issuance i244.8M25.0M070.0M0
Debt Repayment i-107.6M0-975.0K-30.0M0
Financing Cash Flow i127.6M71.2M-975.0K41.2M679.7M
Free Cash Flow i-40.6M-31.4M-176.2M-296.0M-214.9M
Net Change in Cash i64.8M-8.8M-185.8M-271.3M440.7M

Cash Flow Trend

Tg Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 73.47
Forward P/E 28.78
Price to Book 14.67
Price to Sales 9.76
PEG Ratio 0.26

Profitability Ratios

Profit Margin 13.32%
Operating Margin 24.69%
Return on Equity 26.63%
Return on Assets 9.72%

Financial Health

Current Ratio 3.86
Debt to Equity 92.08
Beta 1.95

Per Share Data

EPS (TTM) $0.38
Book Value per Share $1.90
Revenue per Share $3.11

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
tgtx4.4B73.4714.6726.63%13.32%92.08
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.4B-16.98-5.2436.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.